Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05389293 · ClinicalTrials.gov registry record · Phase 2
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
A Phase 2 study of Lymphoma and Follicular Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 9
- Study locations
NCT05389293 is a Phase 2 study of Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 152 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (69% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT05389293, a Phase 2 study of Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Mosunetuzumab
Study Locations (9)
New Jersey
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities - Basking Ridge
- Hackensack Meridian Health (Data collection only) - Hackensack
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
District of Columbia
- Georgetown University (Data Collection Only) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05389293
The ClinicalTrials.gov registry entry for NCT05389293 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (69% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT05389293 reports 9 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, New York, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05389293 about?
NCT05389293 is a clinical study titled "A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma". The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
What is the current status of trial NCT05389293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2022-05-27. Estimated completion is 2026-12.
What conditions does trial NCT05389293 study?
This clinical trial studies the following conditions: Lymphoma, Follicular Lymphoma.
What interventions are being tested in trial NCT05389293?
The interventions under investigation include: Zanubrutinib (DRUG), Mosunetuzumab (DRUG).
Who is sponsoring clinical trial NCT05389293?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05389293 being conducted?
This trial has 9 study locations across District of Columbia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
-
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.